Robert Azelby
CIK 1656998 · President & CEO · last filed 2026-07-01
Robert Azelby is a President & CEO who has filed 48 SEC Form 4 insider transactions across 12 companies since 2015. The most recent filing, for AUTL, was dated Jul 1, 2026. Across all open-market trades the lifetime net is −$14.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 4 SEC filings were submitted jointly with CARDINAL HEALTH INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.22M
12
48
-$14.08M
Filer Profile
DUBLIN, OH 43017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.88 | — | $0 | 1 | 2026-07-01 |
| TNGX | Director | 5,740 | $23.78 | $136.5K | $0 | 1 | 2026-06-23 |
| ADCT | Director | 112,805 | $1.07 | $120.7K | -$20.2K | 5 | 2026-06-03 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 3 | 2026-05-05 |
| CAH | Director | 4,085 | $234.57 | $958.2K | $0 | 3 | 2025-11-06 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | — | $40.39 | — | $0 | 2 | 2023-08-11 |
| Climb Bio, Inc. (ELYM) Delisted | President & CEO | — | $5.11 | — | $0 | 2 | 2022-11-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 4 | 2021-06-11 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 3,718 | — | — | $0 | 3 | 2020-10-23 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | President and CEO | — | — | — | $0 | 3 | 2019-04-25 |
| Juno Therapeutics, Inc. (JUNO) Delisted | EVP & Chief Commercial Officer | 0 | — | — | -$14.06M | 16 | 2018-03-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | — | — | — | $0 | 2 | 2017-06-13 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-01 | AUTL | Grant (A) | — | $0 | EDGAR |
| 2026-06-23 | TNGX | Grant (A) | +5,740 | $0 | EDGAR |
| 2026-06-03 | ADCT | Mixed | +32,400 | -$38.8K | EDGAR |
| 2026-05-05 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-02-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-11-06 | CAH | Grant (A) | +1,067 | $0 | EDGAR |
| 2025-06-17 | ADCT | Tax (F) | −12,600 | -$45.1K | EDGAR |
| 2025-06-05 | ADCT | Grant (A) | +40,000 | $0 | EDGAR |
| 2025-02-24 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-11-07 | CAH | Grant (A) | +1,730 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.